The p53 Laboratory researchers from Singapore's Agency for Science, Technology and Research have presented a research, which will add to the feasibility of the execution of cancer treatment technique.
The research, which appeared in the pioneering online journal Cell Death and Differentiation today, have provided a deep knowledge on how to hit on the properties of p53, which is the chief guardian of the genomes. This will help in removing the cancer cells in more effective manner without affecting normal cells.
The study was led by Dr. Cheok Chit Fang and Prof. David Lane, the co-discoverers of the p53 gene in 1979.
The research team discovered that by activating p53, the cell cycle stops and endoreduplication gets avoided. Endoreduplication is a process that undertakes the accumulation of excess genetic material by the cell through the replication of existing genetic material.
On a disappointing note, the study revealed that if endoreduplication hits human cells, they die.
It was also found that in many cancers, the cancer cells do not have activated copies p53. Various drugs can be used for the activation of p53 in healthy cells and thereby the cell production can be halted temporarily.
Prof David Lane, Director of the p53 Laboratory, said, "We are proposing a unique combination of drugs, which may have therapeutic benefits and could potentially alleviate the side-effects of currently available cancer treatments".